Neuro-Bio was featured in a SelectScience webinar, “How Synthetic Binders Are Transforming Diagnostics and Molecular Biology.”
The webinar explored how synthetic binders are providing effective alternatives where traditional antibodies can fall short. Baroness Susan Greenfield, CEO of Neuro-Bio, discussed how Optimer® technology has supported the development of a highly sensitive Alzheimer’s disease test targeting a novel biomarker.
The session included insights from Aptamer Group and Alphazyme, highlighting real-world applications of synthetic binders in diagnostics, biomarker detection, and molecular biology workflows.
The webinar is available to watch on demand through SelectScience.